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There are still some vascular surgeons who do not use carotid patching routinely in all patients undergoing CEA,
however, based on the data presented in this review, there is Level 1 evidence to support the routine use of carotid
patching. Meanwhile, there is no Level 1 evidence to support selective patching for CEA, however a Grade D
recommendation may be used to recommend that primary closure can be safely practiced in a large ICA (>6mm). A
meta-analysis/systemic review of well-conducted prospective randomized trials (Level 1 evidence) concluded that there
was no difference in stroke/death rates between conventional CEA with patch closure and eversion CEA. The incidence
of significant restenosis with eversion CEA is also similar to CEA with patch closure, however eversion CEA had a lower
restenosis rate than patients undergoing CEA with primary closure. Prior to the GALA trial, there was insufficient
evidence from randomized clinical trials comparing CEA under local anesthesia versus general anesthesia to support the
superiority of either technique in reducing major perioperative events, i.e. stroke, MI, or death. However, the GALA trial
concluded that the perioperative stroke/MI and death rates were equivalent in both techniques. ( J Vasc Surg 2009;50:
921-33.)Stroke remains the third leading cause of death overall,
and the second leading cause of death for women in the
United States.1 Approximately 15% to 52% of all ischemic
strokes are due to extracranial cerebrovascular atheroscle-
rotic lesions.2-3 It has also been estimated that 103,000
carotid endarterectomies (CEA) were done in the United
States in 2005.1
Regardless of which criteria are used to determine
whether CEA is warranted, a surgeon must stay within the
accepted perioperative stroke rate of3% for asymptomatic
carotid artery stenosis, and 7% for symptomatic carotid
artery stenosis (5% for transient ischemic attacks [TIAs]
and 7% for stroke indications), as recommended by the
Ad Hoc Committee of the Stroke Council of the American
Heart Association.4
Few surgical procedures have been scrutinized as thor-
oughly as CEA during the last 2 decades. This scrutiny was
amplified by multiple neurology publications in the late
1970s and mid 1980s that attacked CEA, and by the
Barnett trial that condemned the extracranial-intracranial
bypass operation.5-7 Easton and Sherman5 reported a sur-
gical morbidity and mortality rate of 21% in community
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opponents of CEA. Mark Dyken, in an editorial published
in Stroke in 1986 on carotid endarterectomy studies, con-
cluded that the permanent stroke and mortality rates varied
between 3% and 21%, based on several institution and
community studies.7 This controversy led to the initiation
of several prospective randomized trials in both North
America and Europe that were designed to compare the
safety and efficacy of CEA vs medical therapy.8-11 Collec-
tively, the data from these prospective trials have confirmed
that CEA offers significantly better protection from ipsilat-
eral strokes than medical therapy in a substantial number of
patients presenting with either symptomatic or asymptom-
atic carotid artery disease.
Recently, the Society of Vascular Surgery, in a special
communication, published outlines for the management
of atherosclerotic carotid artery disease that details rec-
ommendations for medical therapy vs CEA/carotid
stenting for both symptomatic and asymptomatic carotid
artery stenosis.12 Several techniques for CEA have
evolved since the first CEA was performed by De Bakey
in 1953 (published in 1959).13 However, certain tech-
nical points, eg, selective vs routine shunting, mode of
cerebral monitoring (electroencephalogram, transcranial
Doppler scan, etc), and intraoperative imaging have a
number of variations on the theme in practice today, and
there is no real evidence base to support one approach
over the other. Therefore, these technical points are not
reviewed herein as the spectrum of current practice is
generally the surgeon’s choice.
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garding CEA: primary vs patch closure, conventional vs
eversion CEA, and CEA under local vs general anesthesia,
with special emphasis on the evidence base in support
thereof.
CEA WITH PRIMARY CLOSURE VS
PATCH CLOSURE
The type of closure after a CEA, primary vs patch
closure, remains controversial.14-40 Most authorities agree
that in a small carotid artery (4 mm), particularly in the
presence of technical difficulties at the internal carotid
artery (ICA) end of the arteriotomy, closing with a patch
may avoid restenosis. It is not infrequent for lateral tears to
occur at the apex of the ICA after making the linear
arteriotomy, and patching may avoid narrowing during
primary closure of the arteriotomy. In patients where there
is excessive thickening of the intima of the distal ICA,
which may extend upward toward the base of the skull,
patching can smooth the transition zone from the CEA site
to the residual artery beyond. Patching may also be advis-
able in patients with kinked or elongated arteries, and may
help maintain the lumen and prevent postoperative occlu-
sion. Patching should also be routinely used for redo CEA.
CEA with patch angioplasty is generally believed to
decrease the chance of technical errors and has been shown
by multiple clinical trials to be more effective than CEA
with primary closure in decreasing the incidence of periop-
erative stroke, perioperative carotid thrombosis, and late
restenosis.14-16,18,20-28 However, many others believe that
inclusion of a patch prolongs the operative time and clamp
or shunt time, makes the procedure technically more de-
manding, and may be unnecessary in some patients.17
Norton and Spencer41 reported on the first comparison
Table I. Results of randomized controlled trials of CEA w
Author/year/reference
No. patch/
primary
Perioperative
stroke/death
(%) patch/
primary Odds ratio (95
De Vleeschauwer/
198714 90/84 0/0 —*
Eikelboom/198815 66/60 4.5/6.7 0.67 (0.15-3.06
Lord/198916 90/50 1.1/6.0** 0.2 (0.0-1.7)
Ranaboldo/199318 96/91 3.2/7.7 0.41 (0.11-1.45
Myers/199419 46/48 0/2.1 0.14 (0.00-7.12
Katz/199420 43/44 2.3/4.5 0.52 (0.05-5.11
AbuRahma/199621 264/135 2.3/6.7 0.3 (0.10-0.88
AbuRahma/199925 74/74 0/4.0 —*
Bond/2004***34
(Cochrane review) 515/378 2.5/6.1 0.40 (0.2-0.8)
Al-Rawi/200638 153/175 4.0/2.9 1.39 (0.42-4.64
No., Number; CI, confidence interval; mos., months.
*Not available or not applicable.
**Only 30-day risk of ipsilateral stroke only.
***This is a meta-analysis of several randomized trials.
****Carotid occlusion only (not 50% restenosis).
*****Wide range of CI indicates poor statistical power.between primary carotid artery closure and patch angio-plasty in animals in 1964, while Imparato42 utilized carotid
vein patching as early as 1965, but reported their results at
a later date.
There have been several randomized controlled trials
(level I evidence) published over the last 2 decades comparing
CEA with patch angioplasty vs primary closure.14-16,18-25,38
Table I summarizes the results of these randomized controlled
trials. As noted in Table I, these randomized trials showed the
superiority of patch closure over primary closure, in reduc-
ing both the perioperative stroke/death and the incidence
of significant restenosis.
One of these randomized trials was unique in the fact
that 74 patients undergoing bilateral sequential CEAs were
randomized to either patching/primary closure or primary
closure/patching, ie, each patient was their own control.
Primary closure had an ipsilateral stroke rate of 4% vs 0% for
CEA with patching; and at a late mean follow-up of 29
months, the incidence of80% restenosis was significantly
higher in the primary closure group.25
In addition, there were two meta-analyses of the ran-
domized controlled carotid trials by the Cochrane Collab-
orative Data Base in 2000 and 2004.28,34 In an earlier
Cochrane meta-analysis of randomized carotid trials, the
early postoperative thrombosis, postoperative stroke, and
50% restenosis were superior for patching, in contrast to
primary closure.28 In an update of the Cochrane Collabo-
rative Data Base in 2004, Bond et al34 reported the out-
come for 1281 patients, including seven controlled carotid
trials. Patch angioplasty was associated with a reduction in
ipsilateral stroke (1.6% vs 4.8% for primary closure, P 
.001), any stroke (1.6% vs 4.5%, P .004), stroke or death
(2.5% vs 6.1%, P  .007), return to the operating room
(1.1% vs 3.1%, P  .01), and arterial occlusion (0.5% vs
3.6%, P  .0001). Also in long-term follow-up, patch
atch closure vs primary closure
50% Restenosis
rate (%) patch/
primary Odds ratio (95% CI) Follow-up (mos.)
1.1/10.7 0.1 (0.0-0.8) 12
11.9/27.4 0.37 (0.16-0.89) 60
—* —* Hospital Discharge
5.5/16.3 0.33 (0.14-0.77) 12
3.2/3.1 1.03 (0.14-7.51) 54
0/5.9 0.14 (0.01-1.33) 29
5.3/33.3 0.11 (0.06-0.19) 30
7/45 0.09 (0.03-0.25) 29
4.8/18.6 0.22 (0.1-0.3)
* 3.3/1.7**** 1.9 (0.46-8.24)***** 12ith p
% CI)
)
)
)
)
)
)****angioplasty was superior to primary closure in the reduction
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(1.9% vs 5.9%, P  .0009), stroke or death (14.6% vs 24%,
P  .004), and late restenosis (4.8% vs 18.6%, P  .0001,
Fig).
Recently, Mannheim et al36 conducted a randomized
controlled trial comparing 216 patients who had CEA with
primary closure vs 206 patients with polyurethane patch
closure. The incidence of70% restenosis was significantly
lower in patients with patch closure vs primary closure
(2.2% vs 8.6%, P  .01).
One interesting article in support of primary closure has
been published recently.38 In this study, primary closure
was performed with an operating microscope and com-
pared to patch closure with a Dacron graft (DuPont, Wil-
mington, Del). Three hundred twenty-eight patients (153
patches vs 175 primary closures) were compared. All CEAs
were performed by a single surgeon. The 30-day perioper-
ative stroke rate was 2.9% for primary closure vs 3.9% for
patch closure. Unfortunately, this study was stopped after
328 patients on the basis of futility. The authors concluded
Fig 1. Summary estimates of treatment effect from al
angioplasty versus primary closure. Review included 119
Bond et al.34that there was no difference in vessel patency and clinicaloutcome after microscopic patch angioplasty and direct
arteriotomy repair. The authors also concluded that there
was no benefit from the routine use of patch angioplasty in
microscopic CEA. It is generally believed that this study did
not have the statistical power to support their conclusions.
Other nonrandomized trials with level 2-4 evidence
have been published that support patching over primary
closure.35,37,39 Rockman et al37 reported the results of a
nonrandomized trial of 1972 CEAs by 81 surgeons in two
states. These included 233 patients with primary closure
and 1377 with patch angioplasty. Primary closure had a
5.6% stroke rate vs 2.2% for patch closure (P  .006). The
authors strongly recommended abandonment of primary
closure. Kresowik et al35 performed a hospital review of a
random sample of 10,000 Medicare patients undergoing
CEA in 10 midwestern states during a 12-month period in
1995-1996 and in 1998-1999. They concluded that stroke
and mortality rates were lower in the second period than in
the first period (5% vs 5.6%, P .05), and two factors were
considered responsible for this improvement; patch closure
a-analysis outcomes from 7 trials that compared patch
ents (1281 operations). Reprinted with permission froml met
3 patiand the increased use of antiplatelet agents (P  .05).
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experience of 2343 CEAs from 1976-2002. They con-
cluded that patching had a lower incidence of ipsilateral
stroke than primary closure (1.1% for vein patch vs 2.8% for
primary closure, P  .028). They also noted that vein and
synthetic patching were similar (P  .10).
Role of selective patching. Selective patching has
been proposed, ie, utilizing it for patients with tortuous or
exceptionally small carotid arteries. There is no level 1
evidence supporting selective patching vs primary closure
or routine patching. Pappas et al43 reported the results of a
retrospective study of 133 CEAs where 77 patients were
closed primarily and 56 patients were patched. Primary
closure was done if the arteriotomy could be closed over a
Javid shunt (C.R. Bard, Tempe, Ariz) without tension,
otherwise the carotid arteries were patched. The stroke rate
for patched arteries was 3.6% vs 0% for primary closure (not
significant), with no difference in long-term restenosis. The
findings of this study were expected given the overall low
incidence of stroke and the small patient numbers.
Golledge et al,44 from the Charing Cross group in London,
reported their experience with selective patching of carotid
arteries that were 5-6 mm. These authors found no
significant difference in stroke or restenosis and advocated
selective patching of carotid arteries. Similarly, Cikrit et al45
reported their experience with selective patching and com-
pared 65 patients with primary closure vs 188 with patch-
ing. The need for patching and the type of patch was left to
the discretion of the surgeon. No significant difference in
early or late outcomes was noted, but because patching was
selectively applied to small arteries, the results are not
surprising.
Patch material/CEA. Selection of CEA patch mate-
rial is also controversial, with supporters for the use of
both vein patches (saphenous or neck veins) and syn-
thetic patches (polytetrafluoroethylene [PTFE] or Da-
cron graft).16,18,21,23,24,29-33
Existing data from randomized controlled trials sug-
gest that the type of patch, whether vein or prosthetic, has
no effect on short-term or long-term results.22,33,34,46
Proponents of vein patch angioplasty (saphenous vein
patch) state that the theoretical benefits include an increase
in luminal size and provision of endothelialized tissue to the
endarterectomy site. Others cite that they prefer an autog-
enous vein over prosthetic materials because the luminal
surface is less thrombogenic and more resistant to infec-
tion.47 It is believed that vein patch angioplasty reduces the
risk of perioperative stroke, recurrent carotid stenosis, or
occlusion.15,16 Opponents to synthetic patches also fear
bleeding through the patch material and thrombus forma-
tion. Although many authorities prefer vein patching, sev-
eral issues have been raised with respect to availability,
increased operative time, morbidity related to harvesting,
vein patch rupture, and late aneurysmal dilatation.23,24
Because of patients’ complaints about ankle harvest inci-
sions, some authorities recommended the abandonment of
vein in favor of prosthesis (Dacron graft).48 Although vein
patches were used in 82% of patients during the first 2 yearsof their study, they comprised 3% of carotid patches
during the most recent 2 years of the study, being replaced
with Dacron graft patches (95%). The type of patch had no
impact on perioperative complication rates.48
The long saphenous vein is the most common autoge-
nous source for carotid vein patch angioplasty, but it is also
in demand for coronary artery bypass grafting and lower
extremity revascularization. To save the saphenous vein for
these procedures, the internal jugular vein has been pro-
posed as an alternative for carotid vein patch angioplasty.47
Some have advocated the use of everted external jugular
veins, where the vein is turned inside out to provide a tube
of vein with intima on the outside.49 This double-walled
patch can then be utilized, which is felt to be stronger and
more resistant to rupture than a single-walled saphenous
vein patch.49
The Cochrane Database update by Bond et al46 re-
ported on seven randomized clinical trials with 1280 pa-
tients.16,23,29,32,33,50,51 Despite this large number, there
was insufficient data to enable definite conclusions about
the optimal patch material, because the adverse events were
so small. The authors concluded that there were no obvious
differences in the perioperative stroke/death rate in pa-
tients receiving vein or synthetic patch, and also no differ-
ence in the long-term follow-up to support either patch.
The risk of major arterial complications, eg, rupture or
infection, was 1% in both groups. Three out of 348
(0.9%) had vein patch blowout, one of which was fatal, in
contrast to two out of 359 (0.6%) with synthetic patches
that sustained rupture, one of which was also fatal.
A meta-analysis by Archie52 supported the superiority
of patching over primary closure. It also showed that CEA
patching with the great saphenous vein had better postop-
erative stroke and restenosis outcomes than a Dacron graft
and PTFE.
O’Hara et al32 reported the results of a randomized
clinical trial of saphenous vein patching (101) vs knitted
Dacron graft patching (94). The stroke rates were similar in
both groups (3% for vein patching vs 2.1% for Dacron
graft). The recurrent stenosis rates were also similar (4.3%
vs 6.3%). The authors concluded that CEA can be safely
performed with either patch. Naylor et al33 also reported
the results of a randomized trial, comparing thin-walled
Dacron graft patch closure (136) vs vein patch closure
(137). The stroke/death rate was 2.2% for Dacron graft vs
3.7% for vein. They noted that the Dacron graft patch had
a significantly higher incidence of carotid restenosis, how-
ever, none of the 11 patients with 70% restenosis were
symptomatic.
Although most studies describe the use of saphenous
vein patching, others prefer external jugular vein patching.
Grego et al53 compared the external jugular vein with
PTFE patching on 160 patients (80 of each). There were
no strokes in the external jugular vein group and one stroke
in the PTFE group (nonsignificant). The restenosis rates
were also similar: 9.8% for the external jugular vein vs 13.3%
for PTFE.
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tional Dacron graft patches or PTFE patches. However,
one of the main criticisms of the conventional PTFE patch
was a prolonged hemostasis time, therefore, a newmodified
PTFE patch was introduced (ACUSEAL, Gore, Flagstaff,
Ariz), which is claimed to have better hemostatic proper-
ties. Similarly, a new ultrathin Dacron graft patch was also
introduced to minimize thrombosis (Finesse; Boston Sci-
entific, Natick, Mass). AbuRahma et al30,31 reported the
results of a prospective randomized clinical trial of CEA
using the conventional PTFE (100) vs conventional
collagen-impregnated Dacron-Hemashield (100)((Bos-
ton Scientific). The perioperative stroke rate was 0% for
PTFE vs 7% for Dacron graft (P  .02). The combined
stroke and TIAs were also higher in the Hemashield
group (P  .03). There were five incidences of periop-
erative carotid thrombosis in the Dacron graft group vs
none in the PTFE group. The restenosis rate was also
higher in patients with Dacron grafts (P  .001). How-
ever, the intraoperative needle hole bleeding time for
PTFE was longer. Recently, AbuRahma et al54 also
reported the results of a prospective randomized trial of
200 CEA patients (100 ACUSEAL and 100 Finesse).
The perioperative stroke rates for both groups were
comparable (2%). The long-term follow-up of the same
study was also published recently,40 which showed that
the stroke-free survival rates were comparable for both
patches, however, the freedom from 70% restenosis at
1, 2, and 3 years was 98%, 96%, and 98%, respectively, for
ACUSEAL vs 92%, 85%, and 79% for the Finesse patch
(P  .04). The difference between the 5-minute hemo-
stasis time for the ACUSEAL patch and the 3.7 minute
hemostasis time for the Finesse patch was statistically
significant, however, its clinical significance is debatable.
Based on several randomized trials conducted at our
institution, I strongly believe that synthetic patches, partic-
ularly the PTFE ACUSEAL and the Finesse Dacron graft
patch, have comparable early and late clinical outcomes to
saphenous vein patching.21,23,25,30,31,40,54
Unfortunately, our experience with the use of bovine
pericardial patching has been limited, however, several
recently published studies have confirmed a favorable clin-
ical outcome using this patch after CEA.55-57
Biasi et al55 reported on their 9-year experience with
the use of bovine pericardial patch angioplasty during CEA.
This was a nonrandomized study that included 517 CEAs
that were divided into 194 primary closures and pericardial
patch angioplasties in 323 procedures. The perioperative
stroke/death rate was 4.1% in the primary closure group vs
1.5% in the pericardial patch group (P  .066). The inci-
dence rate of restenosis/occlusion was significantly lower in
the pericardial patch group, and it was statistically signifi-
cant at 6 months (P .017) and 1 year (P .009), but not
after the second year. None of the patients with restenosis
were symptomatic: 2.7% had restenosis of 80%, and all
underwent reoperation. There were 10 reoperations in the
primary closure group (5.1%) vs four (1.2%) in the bovine
patch group (P  .008).Marien et al56 reported the results of a prospective
randomized study comparing bovine pericardium vs Da-
cron graft for patch angioplasty after CEA. Fifty-one CEAs
were performed using bovine patches and 44 using Dacron
graft patches. Intraoperative suture line bleeding was sub-
jectively evaluated by observing bleeding at 3 and 4 min-
utes after carotid cross-clamping removal, and then objec-
tively weighing the sponge used to tamponade bleeding
during these time intervals. Perioperative stroke rates were
comparable for both groups (2% for the bovine pericardial
patch and 0% for the Dacron graft patch, P  .55), how-
ever, suture line bleeding at 3minutes was present in 14% in
the bovine patch group vs 55% in the Dacron graft group
(P .001). Suture bleeding at 4 minutes was present in 4%
in the bovine patch group vs 30% in the Dacron graft patch
group (P  .001). The authors concluded that bovine
pericardium demonstrated a statistically significant de-
crease in intraoperative suture line bleeding when com-
pared to Dacron graft patching. Recently, Matsagas et al57
reported their experience of 148 CEAs using bovine peri-
cardial patches, with no perioperative deaths and two ipsi-
lateral strokes (1.4%); and during follow-up, 2% developed
asymptomatic significant carotid restenosis. The authors
concluded that bovine pericardial patch is a suitable patch
material for routine use in CEA.57 Table II summarizes the
results of various patches in CEA.
Restenosis after CEAs. The incidence of CEA reste-
nosis ranges from 1% to 41%, depending on the severity of
stenosis (50%,70%, or80%) and the length of follow-
up. It has bimodal occurrence, the first of which is generally
noted between 6 and 24months after the procedure, which
is generally caused by intimal hyperplasia. Early recurrence
can be caused by local factors (technical), eg, clamp trauma
or intimal/medial flaps.58,59 Other causes include female
gender, a small ICA (4 mm), and primary closure of the
arteriotomy site. The second mode is usually noticed after
24 months and is related to systemic factors, such as hyper-
tension, continued smoking, diabetes mellitus, and hyper-
cholesterolemia, which may lead to recurrence of athero-
sclerosis.26,59
Proper identification of the risk factors responsible for
recurrent stenosis is important; the ultimate goal being
reduction of recurrent stenosis via modification of identi-
fied risk factors. It is difficult, however, to draw meaningful
conclusions from the data published to date, because the
majority of patients who undergo CEA have more than one
risk factor present for recurrent disease. Conclusions drawn
from a simple univariate analysis of risk factors in this
population must then be interpreted with great caution.
Multivariate analysis, however, using multiple linear regres-
sion models, allows more definitive conclusions regarding
the impact of individual risk factors and excludes confound-
ing effects of other variables.
Technical imperfections at the time of CEA have been
implicated in the etiology of early restenosis. An analysis of
these technical factors revealed that CEAs closed with patch
angioplasty had a statistically significant lower incidence of
shield
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our previous discussion.
Several studies have suggested that female gender may
play a significant role in CEA restenosis,23,26,59 however,
most of these studies included CEAs with primary closure,
which has been demonstrated to have a higher incidence of
perioperative stroke and late restenosis.60,61
AbuRahma et al23,26 in a prospective randomized trial
using multiple linear regression analyses, noted that the
occurrence of 50% or more stenosis was more strongly
associated with primary closure (P  .001) and female
gender (P  .0051). Female gender was associated with a
20% incidence of50% stenosis in contrast to 11% for male
gender in the whole series (P  .013). No correlation was
found between gender and 50% recurrent stenosis in
patients with PTFE patching or vein patch closure; how-
ever, women with primary closure had a higher recurrent
stenosis rate than men (46% vs 23%, P .008). The carotid
artery diameter at the time of surgery was not significantly
associated with recurrent stenosis and neither were coro-
nary artery disease, serum triglyceride or cholesterol con-
centrations, hypertension, diabetes mellitus, age, or aspirin
therapy.
We also failed to observe significance of serum lipid
concentrations, coronary artery disease, continued smok-
ing, and diabetes mellitus as risk factors for recurrence in
our study, and this is presumably due to the fact that these
represent risk factors for recurrent atherosclerosis and,
therefore, may be implicated in more long-term recur-
rences than we observed in our follow-up period.
Previous studies have suggested that hypertension may
Table II. Results of randomized controlled trials of CEA
Author/year/reference
No.
Perioperative st
death (%)
Dacron/vein patch Dacron/vein p
Katz/199651 107/100 2.8/1.0
Hayes/200129 135/136 2.2/2.2
O’Hara/200232 94/101 3.2/3.9
Naylor/200433 136/137 2.2/3.7
ePTFE/vein patch ePTFE/vein pa
Lord/198916 47/43 2.1/0
González-Fajardo/199450 39/35 5.1/0
AbuRahma/199823 134/130 2.2/2.3
Dacron/ePTFE
patch
Dacron/ePTFE
AbuRahma/2002**31 100/100 7/0
AbuRahma/2008***40 100/100 2/2
CEA, Carotid endarterectomies; No., number; CI, confidence interval; ePT
*Not available or not applicable.
**Conventional PTFE vs collagen-impregnated Dacron graft patch (Hema
***ACUSEAL vs Finesse (Ultrathin Dacron graft) (PTFE).be a significant risk factor for recurrent stenosis.62,63 Be-cause most recurrences occur within 2 years postopera-
tively, it is generally believed that they are the result of local
intimal hyperplasia. Hypertension is known to cause an
exaggerated healing response in experimental models of
arterial injury. In our series, hypertension showed signifi-
cance as a risk factor when the entire population was
examined (P  .0407), however, hypertension failed to
achieve significance as a risk factor when the population was
restricted to subjects who received patch angioplasty. This
is logical, because patching may improve the local flow
characteristics, thus limiting local arterial injury and subse-
quent intimal hyperplasia. Also, the increased diameter of
the vessel after patching may lessen the effect of intimal
hyperplasia, if it should occur. Each of the studies published
to date that demonstrated significance of hypertension as a
risk factor was composedmainly of patients who underwent
primary closure.63
Another factor that has been implicated as a risk factor
for CEA restenosis is a younger age.59,63 Hugl et al59
studied the effect of age and gender on restenosis after 372
CEAs on 344 patients, and concluded that patients with
restenosis were significantly younger (67.8 vs 73.1 years,
P  .005), and that females with restenosis were signifi-
cantly younger than females without restenosis (66.1 vs 74
years, P  .001). When they analyzed their data with
respect to age 70 at the time of surgery, they detected an
incidence of restenosis of 2.8% in males and 6.9% in females
over the age of 70; in contrast to 6.6% in males and 25.7%
in females younger than 70 years (P  .003). The authors
felt that these findings may be representative of the fact that
younger patients with carotid occlusive disease have a par-
aring various patch closures
Odds ratio (95%
CI)
50% Restenosis/
occlusion rate (%) @
1 yr.
Odds ratio (95%
CI)
Dacron/vein patch Dacron/vein patch Dacron/vein patch
2.9 (0.3-10) —* —*
1.0 (0.2-5.1) —* —*
0.8 (1.2-3.7) 6.3/4.3 1.0 (0.3-3.1)
0.6 (0.14-2.54) 12.4/7.2 1.8 (0.8-4.1)
ePTFE/vein patch
—* —* —*
199 (0.0-10) 4/0 19.7 (0.0-50)
1.0 (0.2-4.9) 2.2/8.5 0.2 (0.1-0.9)
Dacron/ePTFE patch
—* 12/2 6.68 (1.46-30.69)
1.0 (0.14-7.24) 4/0 —*
panded polytetrafluoroethylene.
).comp
roke/
atch
tch
patch
FE, exticularly more virulent form of atherosclerosis.
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At the present time, there are still some vascular sur-
geons who do not use carotid patching routinely in all
patients undergoing CEA, however, based on the data
presented in this review, there is level 1 evidence to support
a recommendation (grade A) in favor of routine carotid
patching. Meanwhile, there is no level 1 evidence to sup-
port selective patching for CEA, however a grade D recom-
mendation may be used to recommend that primary clo-
sure can be safely practiced in a large ICA (6 mm).
There is also no difference between the preferential use
of various patch materials, ie, saphenous vein or external
jugular vein vs synthetic patches, eg, PTFE or Dacron graft
patches. However, autogenous saphenous vein patching
usually performs better than the old conventional collagen-
impregnated Dacron graft patch. It is also believed that a
grade A recommendation can be made that the conven-
tional PTFE patch performs better than the conventional
collagen-impregnated Dacron graft in decreasing perioper-
ative stroke/carotid thrombosis and carotid restenosis.
Meanwhile, there were no differences in early perioperative
strokes between the new PTFE patch (ACUSEAL) and the
new ultrathin Dacron graft patch (Finesse); however, late
restenosis rates were better for the ACUSEAL patch.
EVERSION VS CONVENTIONAL CEA
Eversion CEA is an alternative technique that has be-
come popular recently in Europe and in some centers in the
United States. In this procedure, the ICA is completely
transected at its origin at the carotid bifurcation, as origi-
nally described by Kieny et al64 in 1985. Kieny’s technique
generally confines the eversion technique to the ICA only.
However, the Etheredge/Debakey65 technique involved
transecting the common carotid artery and everting both
the internal and external carotid arteries as one.
Proponents of eversion CEA claim that this procedure
facilitates removal of plaque higher up in the ICA. They
also claim that this method has the following advantages:
first, as the endpoint is fully visualized and generally not
sutured, it is easier to detect intimal flaps. Secondly, the
reanastomosis of the ICA to the bulb is technically simple,
and avoids the risk of primary closure of the ICA during
conventional endarterectomy or the need for patching. A
genuine technical benefit of the eversion method is that it
facilitates straightening of coiled or redundant ICAs.
Lastly, this method has been associated with a decrease in
restenosis, although the overall data on the issue of reste-
nosis for the eversion technique are controversial, particu-
larly in women; however, the follow-up is relatively short at
this time.
Proponents of the standard technique point to the
potential disadvantages of eversion CEA, which includes
the need to dissect a longer segment of the ICA for easier
handling of the CEA, which may contribute to a higher
incidence of cranial nerve injuries. Shunting is also more
difficult with eversion CEA than with the conventionaltechnique. High distal intimal flaps may also make eversion
CEA more difficult, and many surgeons, particularly low-
volume CEA surgeons, are or would be uncomfortable
with visualization of the endarterectomy endpoint through
the everted, rather than the filleted open ICA.
Several randomized controlled trials have compared
eversion with conventional CEA.66-72 All of these random-
ized clinical trials supported level 1 evidence confirming
the equivalency of eversion CEA and conventional CEA,
at least in the study endpoints of perioperative results.
VanMaele et al66 compared 100 eversion CEAs with 100
conventional CEAs with saphenous vein patching, with a
combined morbidity and death rate of 4% and 8%, respec-
tively. The incidence of significant restenosis at 9 months
was 1% for eversion CEA vs 2% for CEA with vein patch
closure. Ballotta et al69 compared 86 patients who had
sequential bilateral CEAs, where each case served as its own
control. Eversion CEA was done on one side, and conven-
tional CEA with PTFE closure was done on the other side.
There were no deaths/strokes in the eversion group vs two
strokes (2.3%, P  .12) in the CEA patch group. The
incidence of 50% restenosis at 40 months was 0% in the
eversion group vs 4.7% in the CEA with PTFE patch group
(P .02), with a late carotid occlusion rate at 1 year of 1.2%
vs 7%, respectively (P  .06).66 Ballotta et al69 also com-
pared 169 eversion CEAs with 167 PTFE patch closures
with a 0% stroke/death rate in the eversion group vs 2.9% in
the conventional group (P  .03); however, the incidence
of 50% restenosis was comparable for both groups (1.2%
vs 0%). The patch group had a statistically significant higher
combined recurrent stenosis and occlusion rate (4.9% vs
0%, P  .003).
The largest level 1 evidence study comparing eversion
vs conventional CEA came from the Efficacy of Vasopre-
ssin antagonism in EVERsion carotid Endarterectomy ver-
sus Standard Trial (EVEREST).67,68 This is a multicenter
randomized trial that included 1353 patients, 678 were
allocated to conventional CEA, and 675 were allocated to
eversion CEA. The 30-day perioperative major stroke/
death rates were similar for both groups (1.3%). The 30-day
all stroke rates were also similar (2.2% for eversion CEA vs
1.9% for conventional CEA, P .80). At a mean follow-up
of 33 months, carotid restenosis was noted in 2.8% with
eversion CEA vs 7.9% with primary closure and 1.5% for
CEA with patch closure. The cumulative carotid restenosis
at 4 years was lower in the eversion CEA, compared to the
primary closure group (3.6% vs 9.2%, respectively, P 
.01), however, this difference in restenosis disappeared
when eversion CEA was compared to CEA with patch
angioplasty (2.8% vs 1.5% for 671 eversion and 256 patch
angioplasties, respectively). There were no significant dif-
ferences in the cumulative risk of ipsilateral stroke (3.9% for
eversion vs 2.2% for standard, P  .2) and death (13.1% vs
12.7%). Of the 18 variables that were examined for their
influence on restenosis, eversion CEA (hazard ratio of 0.3,
P .0004) and patch CEA (hazard ratio of 0.2, P .002)
were negative predictors of restenosis using a multivariate
Cox regression analysis. There was also no difference in the
grou
JOURNAL OF VASCULAR SURGERY
October 2009928 AbuRahmaincidence of perioperative TIAs, minor strokes, cranial
nerve injuries, myocardial infarction (MI), or surgical tech-
nical defects. One important limitation of this study is that
their primary analysis combined the conventional group
(primary closure and patched) together.
Another level 1 evidence on this subject was also pro-
vided by the Cochrane Systemic Review72 of five random-
ized trials66-71 that included 2465 patients (2590 arteries).
In this review, except for the EVEREST trial (where the
eversion technique was compared to both patch angio-
plasty and primary closure), only CEA with patch angio-
plasty was considered for comparison to the eversion tech-
nique. This systemic review showed an overall risk of any
perioperative stroke/death of 2.1% (1.7% for eversion CEA
vs 2.6% for conventional CEA) with no significant differ-
ence between both techniques (odds ratio [OR] of 0.44,
95% confidence interval [CI] of 0.10-1.82). There was also
no significant difference in the rates of early carotid occlu-
sion, perioperative MI, and local complications (neck he-
matoma 4.2% for eversion vs 5.5% for conventional CEA;
cranial nerve injury 3.8% for eversion vs 5.6% for conven-
tional CEA). Eversion CEA was associated with a lower
incidence of 50% carotid restenosis during follow-up
(1-69 months), 2.5% vs 5.2%, however, there were no
differences in restenosis rates during follow-up between
eversion CEA vs CEA with patching (2.5% vs 3.9%, P was
nonsignificant). The stroke rates during follow-up did not
differ between the groups (2% vs 2.4%).
Table III summarizes the results of these randomized
trials comparing eversion vs conventional CEA. It should
be noted that the authors of the EVEREST trial (Cao et
al72) conducted a trial that showed no difference in reste-
nosis with eversion vs patch, yet they put together the
Cochrane review that claimed an advantage for the ever-
sion.
Several other nonrandomized prospective studies on
eversion CEA have reported mixed results.73-75 One of
these latest reports is from Massachusetts General Hospi-
tal,74 which reported on the incidence of restenosis after
Table III. Results of randomized clinical trials comparing
Author/year/reference Number conventional/eversion
VanMaele/199466 100/100
Cao/1998 &
200067,68
675/678
Ballotta/199971 167/169
Ballotta/200069 86/86
Cao (Cochrane
Review)/200172
1286/1303***
CEA, Carotid endarterectomies.
*There was a 1.5% restenosis rate for patch closure and 7.9% for primary cl
**The incidence of 50% restenosis and occlusion was 4.9% for convention
***Meta-analysis of several randomized trials.
****There was a 5.2% incidence of50% restenosis in all conventional CEA
with a total of 2590 arteries.eversion vs patch closure where 950 CEAs were performedby the same surgeon, with the adoption of the eversion as
the primary technique as of January, 2001. With a mini-
mum of 1-year follow-up, including duplex scan examina-
tions, 155 patients with primary closure and 135 patients
with eversion CEA were available for analysis. There were
no significant differences in outcomes in terms of strokes
and death or the incidence of significant restenosis. The
authors concluded that surgeons obtaining good results
with patch closure should not adopt eversion in anticipa-
tion of improving restenosis rates.74
Shah and Darling et al75 reported their experience in
1855 patients who underwent 2244 CEAs using the ever-
sion technique. During the same time period, 410 patients
had 474 CEAs by the standard technique. The operative
mortality rate was 1.02% in the eversion group vs 2.2% in
the standard group. The incidence of perioperative stroke
was 0.8% in the eversion group vs 2.3% in the standard
group. The incidence of TIA was 0.9% in the eversion
group vs 2.7% in the standard group. On long-term follow-
up, 60% restenosis was noted in 0.3% in the eversion
group vs 1.1% in the standard group. The authors con-
cluded that eversion CEA can be performed safely with a
low rate of stroke and death, and with a minimal restenosis
rate in short- and long-term follow-up.
There is somewhat controversial data that the eversion
technique can increase the risk of post-CEA hypertension
and the incidence of cranial nerve injuries due to carotid
sinus baroreceptor dysfunction and extensive dissection of
the ICA, wherein the carotid body and carotid sinus nerve
are literally resected.76 These data have not been verified in
most large series.66-71
CONCLUSIONS
Based on the available data, specifically meta-analysis/
systemic review of well-conducted prospective randomized
trials with level 1 evidence, a grade A recommendation can
be made that there is no difference in stroke/death rates
between conventional CEAwith patch closure and eversion
CEA. The incidence of significant restenosis with eversion
ventional CEA with eversion CEA
Perioperative stroke/death (%)
conventional/eversion
50% Restenosis rate (%)
conventional/eversion
8/4 2/1
1.3/1.3 1.5 & 7.9*/2.8
2.9/0 4.9/0**
2.3/0 4.7/0
2.6/1.7 5.2 & 3.9/2.5****
2.8% for eversion CEA.
% for eversion. The 50% restenosis rate only was comparable: 1.2% vs 0%.
ps and 3.9% for patch closure groups: meta-analysis of five randomized trialscon
osure,
al vs 0CEA is also somewhat similar to CEA with patch closure,
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patients undergoing CEA with primary closure.
CEA UNDER LOCAL VS GENERAL
ANESTHESIA
The choice of anesthesia has been controversial since
the inception of CEA in the United States by De Bakey in
1953. Although the initial case was done by De Bakey
under general anesthesia, during the initial stages of this
procedure, cervical block with regional anesthesia was felt
to be critical to the safety of carotid surgery by resulting in
fewer cardiorespiratory complications, preserving cerebro-
vascular autoregulation, and allowing close observation of
any neurologic manifestations during the procedure with
more appropriate and less frequent shunt use.13,77 Per-
forming CEA on awake patients under local anesthesia has
the advantage of accurate clinical assessment of the patient
during the procedure and in the immediate early postoper-
ative period. Hemodynamic swings both with induction of
general anesthesia and upon awakening are also avoided.
One other possible benefit of local anesthesia could be the
increase in systemic blood pressure that may occur after
carotid clamping77 and its effect in maintaining cerebral
perfusion.
Meanwhile, CEA under local anesthesia has its own
disadvantages or limitations. Pain or anxiety during the
proceduremay increase the stress/pain, whichmay result in
an increase in the incidence of perioperative MI. However,
most of these patients frequently receive premedication and
intraoperative sedation and analgesia to minimize this
stress. This stress may also impact the performance of some
surgeons. The ability to assist residents and/or fellows to
perform CEA in training environments may also be nega-
tively affected with the use of regional anesthesia. It has also
been suggested that general anesthetics reduce the cerebral
metabolic rate and may have a neurologic protective effect
in the presence of ischemia;78 electroencephalogram mon-
itoring for selective shunt usage requires general anesthesia.
Local anesthesia for carotid surgery may also result in
needle damage to important structures, eg, vertebral artery
during deep cervical plexus block, phrenic nerve block, or
may result in intravascular injection with associated hema-
toma.79 Most clinics use only a superficial cervical plexus
block for CEA procedures.80
Conflicting results have been published over the last
few decades, some favoring local anesthesia while others
favor general anesthesia. A recent Cochrane Database Sys-
temic Review in 2009,81 analyzed nine randomized trials
involving 812 procedures, and 47 nonrandomized studies
involving 24,181 procedures. A meta-analysis of the nine
randomized studies (812 procedures)82-89 showed that
there was no evidence of a reduction in operative strokes
(2.7% for general anesthesia vs 2.7% for local anesthesia,
P .99), but the use of local anesthesia was associated with
a significant reduction in the 30-day perioperative local
hemorrhage rate (OR of 0.30, 95% CI 0.12-0.77). How-
ever, they felt that the randomized trials were too small to
allow reliable conclusions to be drawn, and in some studiesthe intention to treat analysis was not possible because of
exclusions. Table IV summarizes the results of the random-
ized trials of general vs local anesthesia for CEA.
A meta-analysis of the nonrandomized studies (24,181
procedures) showed that the use of local anesthesia was
associated with significant reductions in the risk of 30-day
perioperative stroke (38 studies), death (42 studies), stroke
or death (27 studies), MI (27 studies), and pulmonary
complications (7 studies). However, the methodologic
quality of the nonrandomized trials was felt to be question-
able. The authors concluded that there was insufficient
evidence from the randomized trials to indicate the superi-
ority of local over general anesthesia.
Perhaps the strongest level 1 evidence yet was recently
published in the General Anesthesia vs Local Anesthesia for
Carotid Surgery (GALA) trial.90 This is a multicenter ran-
domized controlled trial of 3526 patients with symptom-
atic or asymptomatic carotid stenosis from 95 centers in 24
countries. Participants were randomly assigned to CEA
under general (1753) or local (1773) anesthesia between
June, 1999, and October, 2007. The primary outcome was
the proportion of patients with a stroke (including retinal
infarction), MI, or death between randomization and 30
days after surgery. This composite endpoint was noted in
84 (4.8%) patients who underwent CEA with general an-
esthesia vs 80 (4.5%) patients with local anesthesia, which
was not statistically significant. Three events per 1000
treated were prevented with local anesthesia (95% CI 11
to 17; risk ratio of 0.94; 95% CI of 0.7 to 1.27). Both
groups did not significantly differ in regards to length of
hospital stay, quality of life, or the primary outcome in the
subgroup analysis of age and baseline surgical risk. The
primary outcome rate for patients over the age of 75 was
5.3% for general anesthesia vs 4.6% for local anesthesia (P
.741); in contrast to 4.6% for general anesthesia and 4.5%
for local anesthesia in patients below the age of 75 (P 
.741). The primary outcome rate for patients with high
surgical risks was 4.1% for general anesthesia and 4.6% for
local anesthesia; in contrast to 4.7% for general anesthesia
and 4.2% for local anesthesia in patients with baseline low
surgical risk (P .933). However, local anesthesia seems to
be more effective than general anesthesia for patients with
contralateral carotid occlusion. The primary outcome of a
stroke, including retinal infarction, MI, or death at 30 days
was 10% for general anesthesia vs 5% for local anesthesia in
patients with contralateral carotid occlusion (anOR of 0.47
with P .098), in contrast it was 4.3% for general anesthe-
sia and 4.5% for local anesthesia in patients without con-
tralateral carotid occlusion. The authors also indicated that
when their results were added to those of the randomized
trial in the Cochrane Review, there was still no advantage of
local anesthesia vs general anesthesia, with the GALA dom-
inating the analysis by providing 80% of the patient popu-
lation.
One other frequently quoted study favoring local vs
general anesthesia was published by Halm et al.91 This is a
retrospective cohort study of patients undergoing CEA in
1997 and 1998 by 64 surgeons in six New York hospitals
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identified independent clinical characteristics and operative
techniques associated with risk-adjusted rates for combined
death and nonfatal strokes, and all strokes. Death or stroke
occurred in 2.28% of patients without carotid symptoms,
2.93% of those with carotid TIAs, and 7.11% of those with
preoperative stroke. Three clinical factors increased the
risk-adjusted odds of complications: stroke as an indication
of surgery, presence of coronary artery disease, and con-
tralateral carotid stenosis. Two surgical techniques reduced
the risk-adjusted odds of death or stroke: use of local
anesthesia (OR 0.30; 95% CI  0.16-0.58) and patch
closure (OR 0.43; 95% CI  0.24-0.76). The author
concluded that two operative techniques, mainly the use of
local anesthesia and patch closure, may lower the risk of
death or stroke.
Stoner et al,92 using a multivariate model, reported the
outcome of 13,622 CEAs performed during a 3-year pe-
riod (2000-2003) at 123 Veterans Affairs and 13 private
sector academic medical centers. The composite stroke,
death, or cardiac event rate was 4.0%, and the stroke/death
Table IV. A, Perioperative stroke rates of randomized clin
Author/year/reference Local anesthesia no. (%)
Forssell/198984 4/56 (7.1%)
Pluskwa/198987 0/10 (0%)
Prough/198988 0/13 (0%)
Binder/199982 0/27 (0%)
Sbarigia/199989 0/55 (0%)
McCarthy/200486 3/88 (3.8%)
Kasprzak/200685 2/91 (2.2%)
GALA/200890 66/1773 (3.7%)
B, Myocardial infarction rates of randomized clinical trials of CEA
Author/year/reference Local anesthesia no. (%)
Forssell/198984 2/56 (3.6%)
Pluskwa/198987 0/10 (0%)
Prough/198988 0/13 (0%)
Binder/199982 0/27 (0%)
Sbarigia/199989 1/55 (2%)
McCarthy/200486 2/88 (2.3%)
Kasprzak/200685 0/91 (0%)
GALA/200890 9/1771 (0.5%)
C, Perioperative stroke/death rates of randomized clinical trials o
Author/year/reference Local anesthesia no. (%)
Forssell/198984 4/56 (7.1%)
Pluskwa/198987 0/10 (0%)
Prough/198988 0/13 (0%)
Binder/199982 0/27 (0%)
Sbarigia/199989 0/55 (0%)
McCarthy/200486 1/34 (2.9%)
Kasprzak/200685 2/91 (2.2%)
GALA/200890 74/1771 (4.2%)rate was 3.4%. Regional anesthesia was used in 2437 (18%)of cases, with a resultant relative risk reduction for stroke of
17%, death (24%), cardiac events (33%), and the composite
outcome (31%); OR 0.69; P  .008. The authors con-
cluded that the use of regional anesthesia significantly
reduced perioperative complications in a risk-adjusted
model, suggesting that it is the anesthetic of choice when
CEA is performed in high- risk surgical patients.92 It should
be noted that because this study was neither randomized
nor designed to study the impact of local vs general anes-
thesia, its conclusions should be interpreted with caution.
CONCLUSIONS
Before the GALA trial, there was insufficient evidence
from randomized clinical trials comparing CEA under local
anesthesia vs general anesthesia to support the superiority
of either technique in reducing major perioperative events,
ie, stroke, MI, or death. The GALA trial concluded that the
major perioperative complications of stroke/MI and death
were equivalent in both techniques. Similarly, there was no
definite evidence that the type of anesthesia affects the
length of hospital stay or quality of life. Nonrandomized
trials of CEA under local vs general anesthesia
General anesthesia no. (%)
Odds ratio
(95% confidence interval)
2/55 (3.6%) 1.97 (0.38-10.15)
1/10 (10 %) 0.14 (0.00-6.82)
0/10 (0 %) 0.0 (0.0-0.0)
0/19 (0 %) 0.0 (0.0-0.0)
2/52 (3.9 %) 0.13 (0.01-2.03)
3/88 (3.8 %) 1.00 (0.20-5.07)
1/95 (1.1 %) 2.05 (0.21-19.96)
70/1753 (4%) 0.94 (0.7-1.27)
er local vs general anesthesia
General anesthesia no. (%)
Odds ratio
(95% confidence interval)
1/55 (2%) 1.94 (0.20-9.01)
0/10 (0%) 0.0 (0.0-0.0)
0/10 (0%) 0.0 (0.0-0.0)
1/19 (5.3%) 0.0 (0.0-0.0)
2/52 (3.9%) 0.48 (0.05-4.70)
2/88 (2.3%) 1.00 (0.14-7.22)
0/95 0.0 (0.0-0.0)
4/1752 (0.2%) 2.23 (0.69-7.26)
under local vs general anesthesia
General anesthesia no. (%)
Odds ratio
(95% confidence interval)
3/55 (5.4%) 1.33 (0.29-6.09)
1/10 (10%) 0.14 (0.00-6.82)
0/10 (0%) 0.0 (0.0-0.0)
0/19 (0%) 0.0 (0.0-0.0)
4/52 (7.7%) 0.12 (0.02-0.88)
1/33 (3%) 0.97 (0.06-15.85)
2/95 (2.1%) 1.04 (0.14-7.54)
81/1752 (4.6%) 0.94 (0.7-1.27)ical
und
f CEAclinical trials suggest potential benefits of local anesthesia
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flaws of retrospective review.
AUTHOR CONTRIBUTIONS
Conception and design: AA
Analysis and interpretation: Not applicable
Data collection: Not applicable
Writing the article: AA
Critical revision of the article: AA
Final approval of the article: AA
Statistical analysis: Not applicable
Obtained funding: Not applicable
Overall responsibility: AA
REFERENCES
1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al.
Heart disease and stroke statistics – 2008 update: a report from the
American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation 2008;117:e25-146.
2. Pessin MS, Duncan GW, Mohr JP, Poskanzer DC. Clinical and angio-
graphic features of carotid transient ischemic attacks. N Engl J Med
1977;296:358-62.
3. Mohr JP. Transient ischemic attacks and the prevention of strokes.
N Engl J Med 1978;299:93-5.
4. Moore WS, Barnett HJ, Beebe HG, Bernstein EF, Brener BJ, Brott T,
et al. Guidelines for carotid endarterectomy. A multidisciplinary con-
sensus statement for the Ad Hoc Committee, American Heart Associ-
ation. Circulation 1995;91:566-79.
5. Easton JD, Sherman DG. Stroke and mortality rate in carotid endarter-
ectomy: 228 consecutive operations. Stroke 1977;8:565-8.
6. [No authors listed] Failure of extracranial-intracranial arterial bypass to
reduce the risk of ischemic stroke. Results of an international random-
ized trial. The EC/IC Bypass Study Group. N Engl J Med 1985;313:
1191-200.
7. Dyken ML. Carotid endarterectomy studies: a glimmering of science.
Stroke 1986;17:355-8.
8. [No authors listed] North American Symptomatic Carotid Endarterec-
tomy Trial. Methods, patient characteristics, and progress. Stroke 1991;
22:711-20.
9. [No authors listed] MRC European Carotid Surgery Trial: interim
results for symptomatic patients with severe (70-99%) or with mild
(0-29%) carotid stenosis. European Carotid Surgery Trialists’ Collabo-
rative Group. Lancet 1991;337:1235-43.
10. [No authors listed] Endarterectomy for asymptomatic carotid artery
stenosis. Executive Committee for the Asymptomatic Carotid Athero-
sclerosis Study. JAMA 1995;273:1421-8.
11. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al.
Prevention of disabling and fatal strokes by successful carotid endarter-
ectomy in patients without recent neurological symptoms: randomized
controlled trial. [Erratum appears in Lancet 2004;364:416]. Lancet
2004;363:1491-502.
12. Hobson RW 2nd, Mackey WC, Ascher E, Murad MH, Calligaro KD,
Comerota AJ, et al. Management of atherosclerotic carotid artery
disease: clinical practice guidelines of the Society for Vascular Surgery. J
Vasc Surg 2008;48:480-6.
13. De Bakey ME, Crawford ES, Cooley DA, Morris GC Jr. Surgical
considerations of occlusive disease of innominate, carotid, subclavian,
and vertebral arteries. Ann Surg 1959;149:690-710.
14. De Vleeschauwer P,WirthleW,Höller L, Krause E,Horsch S. Is venous
patch grafting after carotid endarterectomy able to reduce the rate of
restenosis? Prospective randomized pilot study with stratification. Acta
Chir Belg 1987;87:242-6.
15. Eikelboom BC, Ackerstaff RG, Hoeneveld H, Ludwig JW, Teeuwen C,
Vermeulen FE, Welten RJ. Benefits of carotid patching: a randomized
study. J Vasc Surg 1988;7:240-7.
16. Lord RS, Raj TB, Stary DL, Nash PA, Graham AR, Goh KH. Compar-
ison of saphenous vein patch, polytetrafluoroethylene patch, and directarteriotomy closure after carotid endarterectomy. Part I. Perioperative
results. J Vasc Surg 1989;9:521-9.
17. Clagett GP, Patterson CB, Fisher DF Jr, Fry RE, Eidt JF, Humble TH,
Fry WJ. Vein patch versus primary closure for carotid endarterectomy. J
Vasc Surg 1989;9:213-23.
18. Ranaboldo CJ, Barros D’Sa AA, Bell PR, Chant AD, Perry PM. Ran-
domized controlled trial of patch angioplasty for carotid endarterec-
tomy. The Joint Vascular Research Group. Br J Surg 1993;80:1528-30.
19. Myers SI, Valentine RJ, Chervu A, Bowers BL, Clagett GP. Saphenous
vein patch versus primary closure for carotid endarterectomy: long-term
assessment of a randomized prospective study. J Vasc Surg 1994;19:
15-22.
20. Katz D, Snyder SO, Gandhi RH, Wheeler JR, Gregory RT, Gayle RG,
Parent FN 3rd. Long-term follow-up for recurrent stenosis: a prospec-
tive randomized study of expanded polytetrafluoroethylene patch an-
gioplasty versus primary closure after carotid endarterectomy. J Vasc
Surg 1994;19:198-203; discussion 204-5.
21. AbuRahma AF, Khan JH, Robinson PA, Saiedy S, Short YS, Boland JP,
et al. Prospective randomized trial of carotid endarterectomy with
primary closure and patch angioplasty with saphenous vein, jugular
vein, and polytetrafluoroethylene: perioperative (30-day) results. J Vasc
Surg 1996;24:998-1006; discussion 1006-7.
22. Counsell CE, Salinas R, Naylor R, Warlow CP. A systematic review of
the randomized trials of carotid patch angioplasty in carotid endarter-
ectomy. Eur J Vasc Endovasc Surg 1997;13:345-54.
23. AbuRahma AF, Robinson PA, Saiedy S, Khan JH, Boland JP. Prospec-
tive randomized trial of carotid endarterectomy with primary closure
and patch angioplasty with saphenous vein, jugular vein, and polytetra-
fluoroethylene: long-term follow-up. J Vasc Surg 1998;27:222-32;
discussion 233-4.
24. Archie JP. Prospective randomized trials of carotid endarterectomywith
primary closure and patch reconstruction: the problem is power. J Vasc
Surg 1997;25:1118-20.
25. AbuRahma AF, Robinson PA, Saiedy S, Richmond BK, Khan J. Pro-
spective randomized trial of bilateral carotid endarterectomies: primary
closure versus patching. Stroke 1999;30:1185-9.
26. AbuRahma AF, Robinson PA, Richmond BK. Reanalysis of factors
predicting recurrent stenosis in a prospective randomized trial of carotid
endarterectomy comparing primary closure and patch closure. Vasc
Surg 2000;34:319-29.
27. Archie JP Jr. A fifteen-year experience with carotid endarterectomy after
a formal operative protocol requiring highly frequent patch angioplasty.
J Vasc Surg 2000;31:724-35.
28. Counsell C, Salinas R, Warlow C, Naylor R. Patch angioplasty versus
primary closure for carotid endarterectomy. Cochrane Database Syst
Rev 2000;(2):CD000160.
29. Hayes PD, AllroggenH, Steel S, ThompsonMM, London NJ, Bell PR,
Naylor AR. Randomized trial of vein versus Dacron patching during
carotid endarterectomy: influence of patch type of postoperative embo-
lization. J Vasc Surg 2001;33:994-1000.
30. AbuRahma AF, Hannay RS, Khan JH, Robinson PA, Hudson JK, Davis
EA. Prospective randomized study of carotid endarterectomy with poly-
tetrafluoroethylene versus collagen-impregnated Dacron (Hemashield)
patching: perioperative (30-day) results. J Vasc Surg 2002;35:125-30.
31. AbuRahma AF, Hopkins ES, Robinson PA, Deel JT, Agarwal S. Pro-
spective randomized trial of carotid endarterectomy with polytetrafluo-
roethylene versus collagen-impregnated Dacron (Hemashield) patch-
ing: late follow-up. Ann Surg 2003;237:885-92; discussion 892-3.
32. O’Hara PJ, Hertzer NR, Mascha EJ, Krajewski LP, Clair DG, Ouriel K.
A prospective, randomized study of saphenous vein patching versus
synthetic patching during carotid endarterectomy. J Vasc Surg 2002;
35:324-32.
33. Naylor R, Hayes PD, Payne DA, AllroggenH, Steel S, ThompsonMM,
et al. Randomized trial of vein versus Dacron patching during carotid
endarterectomy: long-term results. J Vasc Surg 2004;39:985-93; dis-
cussion 993.
34. Bond R, Rerkasem K, Naylor AR, AbuRahma AF, Rothwell PM.
Systematic review of randomized controlled trials of patch angioplasty
versus primary closure and different types of patch materials during
carotid endarterectomy. J Vasc Surg 2004;40:1126-35.
JOURNAL OF VASCULAR SURGERY
October 2009932 AbuRahma35. Kresowik TF, Bratzler DW, Kresowik RA, Hendel ME, Grund SL,
Brown KR, Nilasena D. Multistate improvement in process and out-
comes of carotid endarterectomy. J Vasc Surg 2004;39:372-80.
36. Mannheim D, Weller B, Vahadim E, Karmeli R. Carotid endarterec-
tomy with a polyurethane patch versus primary closure: a prospective
randomized study. J Vasc Surg 2005;41:403-7; discussion 407-8.
37. Rockman CB, Halm EA, Wang JJ, Chassin MR, Tuhrim S, Formisano
P, Riles TS. Primary closure of the carotid artery is associated with
poorer outcomes during carotid endarterectomy. J Vasc Surg 2005;42:
870-7.
38. Al-Rawi PG, Turner CL, Waran V, Ng I, Kirkpatrick PJ. A randomized
trial of synthetic patch versus direct primary closure in carotid endarter-
ectomy. Neurosurgery 2006;59:822-8; discussion 828-9.
39. Hertzer NR, Mascha EJ. A personal experience with coronary artery
bypass grafting, carotid patching, and other factors influencing the
outcome of carotid endarterectomy. J Vasc Surg 2006;43:959-68.
40. AbuRahma AF, Stone PA, Elmore M, Flaherty SK, Armistead L,
AbuRahma Z. Prospective randomized trial of ACUSEAL (Gore-Tex)
vs Finesse (Hemashield) patching during carotid endarterectomy: long-
term outcome. J Vasc Surg 2008;48:99-103.
41. Norton LW, Spencer FC. Long-term comparison of vein patch with
direct suture. Technique of anastomosis of small arteries. Arch Surg
1964;89:1083-8.
42. Imparato AM. The role of patch angioplasty after carotid endarterec-
tomy. J Vasc Surg 1988;7:715-6.
43. Pappas D, Hines GL, Yoonah Kim E. Selective patching in carotid
endarterectomy: is patching always necessary? J Cardiovasc Surg
(Torino) 1999;40:555-9.
44. Golledge J, Cuming R, Davies AH, Greenhalgh RM. Outcome of
selective patching following carotid endarterectomy. Eur J Vasc Endo-
vasc Surg 1996;11:458-63.
45. Cikrit DF, Larson DM, Sawchuk AP, Thornhill C, Shafique S, Nachre-
iner R. Discretionary carotid patch angioplasty leads to good results.
Am J Surg 2006;192:e46-50.
46. Bond R, Rerkasem K, Naylor R, Rothwell PM. Patches of different
types for carotid patch angioplasty. Cochrane Database Syst Rev 2004;
(2):CD000071.
47. Seabrook GR, Towne JB, Bandyk DF, Schmitt DD, Cohen EB. Use of
the internal jugular vein for carotid patch angioplasty. Surgery 1989;
106:633-7; discussion 637-8.
48. LaMuraglia GM, Brewster DC, Moncure AC, Dorer DJ, Stoner MC,
Trehan SK, et al. Carotid endarterectomy at the millennium: what
interventional therapy must match. Ann Surg 2004;240:535-44; dis-
cussion 544-6.
49. Yu A, Dardik H, Wolodiger F, Raccuia J, Kapadia I, Sussman B, et al.
Everted cervical vein for carotid patch angioplasty. J Vasc Surg 1990;
12:523-6.
50. González-Fajardo JA, Pérez JL, Mateo AM. Saphenous vein patch
versus polytetrafluoroethylene patch after carotid endarterectomy.
J Cardiovasc Surg (Torino) 1994;35:523-8.
51. Katz SG, Kohl RD. Does the choice of material influence early morbid-
ity in patients undergoing carotid patch angioplasty? Surgery 1996;119:
297-301.
52. Archie JP Jr. Patching with carotid endarterectomy: when to do it and
what to use. Semin Vasc Surg 1998;11:24-9.
53. Grego F, Antonello M, Lepidi S, Bonvini S, Deriu GP. Prospective,
randomized study of external jugular vein patch versus polytetrafluoro-
ethylene patch during carotid endarterectomy: perioperative and long-
term results. J Vasc Surg 2003;38:1232-40.
54. AbuRahma AF, Stone PA, Flaherty SK, AbuRahma Z. Prospective
Randomized Trial of ACUSEAL (Gore-Tex) versus Hemashield-
Finesse patching during carotid endarterectomy: early results. J Vasc
Surg 2007;45:881-4.
55. Biasi GM, Sternjakob S, Mingazzini PM, Ferrari SA. Nine-year experi-
ence of bovine pericardium patch angioplasty during carotid endarter-
ectomy. J Vasc Surg 2002;36:271-7.
56. Marien BJ, Raffetto JD, Seidman CS, LaMorte WW, Menzoian JO.
Bovine pericardium vs Dacron for patch angioplasty after carotid end-
arterectomy: a prospective randomized study. Arch Surg 2002;137:
785-8.57. Matsagas MI, Bali C, Arnaoutoglou E, Papakostas JC, Nassis C, Pap-
adopoulos G, Kappas AM. Carotid endarterectomy with bovine peri-
cardium patch angioplasty: mid-term results. Ann Vasc Surg 2006;20:
614-9.
58. Ouriel K, Green RM. Clinical and technical factors influencing recur-
rent carotid stenosis and occlusion after endarterectomy. J Vasc Surg
1987;5:702-6.
59. Hugl B, Oldenburg WA, Neuhauser B, Hakaim AG. Effect of age and
gender on restenosis after carotid endarterectomy. Ann Vasc Surg
2006;20:602-8.
60. Akbari CM, Pulling MC, Pomposelli FB Jr, Gibbons GW, Campbell
DR, Logerfo F. Gender and carotid endarterectomy: does it matter? J
Vasc Surg 2000;31:1103-8; discussion 1108-9.
61. Liapis CD, Kakisis JD, Kostakis AG. Recurrent carotid artery stenosis:
natural history and predisposing factors. A long-term follow-up study.
Int Angiol 2001;20:330-6.
62. Avramovic JR, Fletcher JP. The incidence of recurrent carotid stenosis
after carotid endarterectomy and its relationship to neurological events.
J Cardiovasc Surg (Torino) 1992;33:54-8.
63. Clagett GP, Rich NM, McDonald PT, Salander JM, Youkey JR, Olson
DW, Hutton JE Jr. Etiologic factors for recurrent carotid artery steno-
sis. Surgery 1983;93:313-8.
64. Kieny R, Hirsch D, Seiller C, Thiranos JC, Petit H. Does carotid
eversion endarterectomy and reimplantation reduce the risk of resteno-
sis? Ann Vasc Surg 1993;7:407-13.
65. Etheredge SN. A simple technic for carotid endarterectomy. Am J Surg
1970;120:275-8.
66. VanMaele RG, Van Schil PE, DeMaeseneer MG, Meese G, Lehert P,
Van Look RF. Division-endarterectomy-anastomosis of the internal
carotid artery: a prospective randomized comparative study. Cardiovasc
Surg 1994;2:573-81.
67. Cao P, Giordano G, De Rango P, Zannetti S, Chiesa R, Coppi G, et al.
A randomized study on eversion versus standard carotid endarterec-
tomy: study design and preliminary results: the EVEREST Trial. J Vasc
Surg 1998;27:595-605.
68. Cao P, Giordano G, De Rango P, Zannetti S, Chiesa R, Coppi G, et al.
Eversion versus conventional carotid endarterectomy: late results of a
prospective multicenter randomized trial. J Vasc Surg 2000;31(1 Pt
1):19-30.
69. Ballotta E, Renon L, Da Giau G, Toniato A, Baracchini C, Abbruzzese
E, et al. A prospective randomized study on bilateral carotid endarter-
ectomy: patching versus eversion. Ann Surg 2000;232:119-25.
70. Balzer K, Guds I, Heger J, Jahnel B. Conventional thromboendarter-
ectomy with carotid patch plasty vs. eversion endarterectomy: tech-
nique, indications and results. [Article in German] Zentralbl Chir
2000;125:228-38.
71. Ballotta E, Da Giau G, Saladini M, Abbruzzese E, Renon L, Toniato A.
Carotid endarterectomy with patch closure versus carotid eversion
endarterectomy and reimplantation: a prospective randomized study.
Surgery 1999;125:271-9.
72. Cao P, De Rango P, Zannetti S, Giordano G, Ricci S, Celani MG.
Eversion versus conventional carotid endarterectomy for preventing
stroke. Cochrane Library, Issue 3, 2001, Oxford: update software.
73. Katras T, Baltazar U, RushDS, SutterfieldWC,Harvill LM, Stanton PE
Jr. Durability of eversion carotid endarterectomy: comparison with
primary closure and carotid patch angioplasty. J Vasc Surg 2001;34:
453-8.
74. Crawford RS, Chung TK,Hodgman T, Pedraza JD, CoreyM, Cambria
RP. Restenosis after eversion vs patch closure carotid endarterectomy. J
Vasc Surg 2007;46:41-8.
75. Shah DM, Darling RC 3rd, Chang BB, Paty PS, Kreienberg PB, Lloyd
WE, Leather RP. Carotid endarterectomy by eversion technique: its
safety and durability. Ann Surg 1998;228:471-8.
76. Metha M, Rahmani O, Dietzek AM, Mecenas J, Scher LA, Friedman
SG, et al. Eversion technique increases the risk for post-carotid endar-
terectomy hypertension. J Vasc Surg 2001;34:839-45.
77. McCleary AJ, Dearden NM, Dickson DH, Watson A, Gough MJ. The
differing effects of regional and general anaesthesia on cerebral metab-
olism during carotid endarterectomy. Eur J Vasc Endovasc Surg 1996;
12:173-81.
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 4 AbuRahma 93378. Wells BA, Keats AS, Cooley DA. Increased tolerance to cerebral isch-
emia produced by general anesthesia during temporary carotid occlu-
sion. Surgery 1963;54:216-23.
79. Hakl M, Michalek P, Sevcík P, Pavlíková J, Stern M. Regional anaes-
thesia for carotid endarterectomy: an audit over 10 years. Br J Anaesth
2007;99:415-20.
80. Pandit JJ, Satyra-Krishna R, Gration P. Superficial or deep cervical
plexus block for carotid endarterectomy: a systematic review of compli-
cations. Br J Anaesth 2007;99:159-69.
81. Rerkasem K, Rothwell PM (The Cochrane Collaboration). Local versus
general anaesthesia for carotid endarterectomy (Review). The Cochrane
Library 2009;1:1-84.
82. Binder M, Fitzgerald R, Fried H, Schwarz S. Carotid endarterectomy
surgery in cervical block: an economic alternative to general anaesthesia?
Gesundheitsokonomie & Qualtitatsmanagement 1999;4:19-24.
83. Forssell C. Studies on risks and results in carotid artery surgery (disser-
tation). Malmo, Sweden: Lund University, 1991.
84. Forssell C, Takolander R, Bergqvist D, Johansson A, Persson NH.
Local versus general anaesthesia in carotid surgery. A prospective,
randomized study. Eur J Vasc Surg 1989;3:503-9.
85. Kasprzak PM, Altmeppen J, Angerer M, Mann S, Mackh J, Töpel I.
General versus locoregional anesthesia in carotid surgery: a prospective
randomised trial. VASA 2006;35:232-8.
86. McCarthy RJ, Trigg R, John C, Gough MJ, Horrocks M. Patient
satisfaction for carotid endarterectomy performed under local anaesthe-
sia. Eur J Vasc Endovasc Surg 2004;27:654-9.87. Pluskwa F, Bonnet F, Abhay K, Touboul C, Rey B, Marcandoro J,
Becquemin JB. [Comparison of blood pressure profiles with flunitrazepam/fentanyl/nitrous oxide vs cervical epidural anesthesia in surgery of the
carotid artery] [Article in French] Ann Fr Anesth Reanimation
1989;8:26-32.
88. Prough DS, Scuderi PE, McWhorter JM, Balestrieri FJ, Davis CH Jr,
Stullken EH. Hemodynamic status following regional and general
anesthesia for carotid endarterectomy. J Neurosurg Anesthesiol 1989;
1:35-40.
89. Sbarigia E, DarioVizza C, AntoniniM, Speziale F,Maritti M, Fiorani R,
et al. Locoregional versus general anesthesia in carotid surgery: is there
an impact on perioperative myocardial ischemia? Results of a prospec-
tive monocentric randomized trial. J Vasc Surg 1999;30:131-8.
90. GALA Trial Collaborative Group, Lewis SC, Warlow CP, Bodenham
AR, Colam B, Rothwell PM, et al. General anaesthesia versus local
anaesthesia for carotid surgery (GALA): a multicentre, randomised
controlled trial. Lancet 2008;372:2132-42.
91. Halm EA, Hannan EL, Rojas M, Tuhrim S, Riles TS, Rockman CB,
Chassin MR. Clinical and operative predictors of outcomes of carotid
endarterectomy. J Vasc Surg 2005;42:420-8.
92. Stoner MC, Abbott WM, Wong DR, Hua HT, Lamuraglia GM,
Kwolek CJ, et al. Defining the high-risk patient for carotid endarter-
ectomy: an analysis of the prospective National Surgical Quality
Improvement Program database. J Vasc Surg 2006;43:285-95; discus-
sion 295-6.Submitted Mar 25, 2009; accepted Apr 23, 2009.
